Multiple episodes of P. vivax relapse were reported in a patient who was an intermediate metabolizer with less than 50% CYP2D6 activity and treated with high-dose primaquine (30 mg daily for 14 days) to prevent malaria recurrence [21]. This evidence concerns the gene CYP2D6 and malaria.